Previous Close | 4.1600 |
Open | 4.1700 |
Bid | 4.2200 x 200 |
Ask | 4.2500 x 100 |
Day's Range | 4.1700 - 4.2550 |
52 Week Range | 2.5700 - 6.0900 |
Volume | |
Avg. Volume | 437,929 |
Market Cap | 233.12M |
Beta (5Y Monthly) | 1.85 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.9100 |
Earnings Date | May 13, 2024 - May 17, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 13.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for CRMD
BERKELEY HEIGHTS, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will be participating in a fireside chat and investor meetings at the Needham 23rd Annual Healthcare Conference, being held virtually on April 8 – 11, 2024. Needham 23rd Annual Healthcare Conference Date: Monda
Net Loss Widens in Q4 and Full Year 2023; Company Prepares for Commercial Launch
Conference Call Scheduled for Today at 8:30 a.m. Eastern TimeBERKELEY HEIGHTS, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on its business. Recent Corporate Highlights: On November 15, 2